Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 791 to 800 of 1447 total matches.
Pneumococcal Vaccine (Prevnar) For Otitis Media
The Medical Letter on Drugs and Therapeutics • Mar 31, 2003 (Issue 1153)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1153B ...
The heptavalent pneumococcal conjugate vaccine (Prevnar - Wyeth) previously approved by the FDA for prevention of invasive pneumococcal disease in infants and children (Medical Letter 2000; 42:25) has now also been approved for prevention of otitis media. Infants and young children have higher antibody responses to the heptavalent conjugate vaccine (PCV7) than to the older 23-valent pneumococcal polysaccharide vaccine (PPV23) used in adults and older children (D Murray and C Jackson, Mil Med 2002; 167:671).
Montelukast (Singulair) for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003 (Issue 1152)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1152A ...
Montelukast (Singulair - Merck), a leukotriene receptor antagonist already marketed for asthma (Treatment Guidelines from The Medical Letter 2002; 1:11), has been approved by the FDA for treatment of seasonal allergic rhinitis in adults and children more than 2 years old.
Anastrozole (Arimidex) vs. Tamoxifen for Treatment of Early Breast Cancer
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003 (Issue 1152)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1152B ...
Anastrozole (Arimidex - AstraZeneca, Medical Letter 1996; 38:61), an aromatase inhibitor, has received accelerated approval from the FDA for adjuvant treatment of postmenopausal women with early hormone-receptor-positive breast cancer. The drug was approved for treatment of postmenopausal women with metastatic breast cancer in 1996.
Drug-eluting Stents
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003 (Issue 1152)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1152C ...
Most angioplasty procedures for coronary artery disease now include placement of stents, which have improved both short- and long-term success rates. The main limitation is restenosis, which occurs in about 25% of patients. Drug-eluting stents intended to reduce the incidence of restenosis have been approved for use in Europe, but not yet in the US.
Three New Drugs for Hyperlipidemia
The Medical Letter on Drugs and Therapeutics • Mar 03, 2003 (Issue 1151)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1151A ...
The FDA recently approved three new drugs for treatment of hyperlipidemia. Ezetimibe (ez et' i mibe; Zetia) is the first in a new class of drugs that inhibit intestinal absorption of cholesterol. Extended-release lovastatin (Altocor) is a new formulation of lovastatin (Mevacor, and others). Extended-release niacin plus (immediate-release) lovastatin (Advicor) is the first fixed-dose combination of lipid-lowering drugs.
Peginterferon Alfa-2a (Pegasys) for Chronic Hepatitis C
The Medical Letter on Drugs and Therapeutics • Mar 03, 2003 (Issue 1151)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1151B)
Mach ...
The FDA has approved recombinant interferon alfa-2a conjugated to polyethylene glycol (Pegasys - Roche) alone or with oral ribavirin (Copegus - Roche) for treatment of adults with chronic hepatitis C virus (HCV) infections not previously treated with interferon alpha. The standard of care for treatment of most patients with hepatitis C has been once-weekly injections of peginterferon alfa-2b (PEG-Intron -Schering) plus oral ribavirin (Rebetol - Schering) (Medical Letter 2001; 43:54).
Drugs of Choice for Cancer
Treatment Guidelines from The Medical Letter • Mar 01, 2003 (Issue 7)
. (ISSN 1541-2784)
Vol. 1 (Issue 7) March 2003
Published by The Medical Letter, Inc.
1000 Main ...
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer...
Buprenorphine: An alternative to Methadone
The Medical Letter on Drugs and Therapeutics • Feb 17, 2003 (Issue 1150)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1150A ...
The FDA has approved the marketing of buprenorphine in sublingual tablets (Reckitt Benckiser) both alone (Subutex) and with naloxone (Suboxone) for treatment of opioid dependence. Previously available only for parenteral use in treatment of pain (Buprenex, and others), it offers an alternative to methadone (Dolophine, and others), which is now often abused (New York Times, February 9, 2003; page 1). As a schedule III narcotic, buprenorphine will be subject to fewer prescribing restrictions than a schedule II drug such as methadone (MJ Kreek and FJ Vocci, J Subst Abuse Treat 2002;...
Aripiprazole (Abilify) for Schizophrenia
The Medical Letter on Drugs and Therapeutics • Feb 17, 2003 (Issue 1150)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1150B ...
Aripiprazole (Abilify - Bristol-Myers Squibb/Otsuka), a quinolinone derivative, has been approved by the FDA for treatment of schizophrenia.
Teriparatide (Forteo) for Osteoporosis
The Medical Letter on Drugs and Therapeutics • Feb 03, 2003 (Issue 1149)
Letter, Inc. • 1000 Main Street, New Rochelle, NY 10801 • A Nonprofit Publication
Vol. 45 (W1149A ...
Teriparatide (ter i par' a tide; Forteo - Lilly), a recombinant segment of human parathyroid hormone, has been approved by the FDA for parenteral treatment of osteoporosis in post-menopausal women, and in men with idiopathic or hypogonadal osteoporosis, who are at high risk for fracture. Teriparatide is the first approved treatment for osteoporosis that stimulates bone formation. Other drugs approved for this indication inhibit bone resorption (Treatment Guidelines from the Medical Letter 2002;1:13).